SLC12A4 Antibody

What is SLC12A4 and why is it an important research target?

SLC12A4, also known as KCC1 (K-Cl cotransporter 1), is a member of the solute carrier family 12 that mediates electroneutral potassium-chloride cotransport across cell membranes. It plays critical roles in:

• Cell volume homeostasis regulation

• Electrolyte balance maintenance

• Basolateral Cl(-) exit in NaCl absorbing epithelia

SLC12A4 is ubiquitously expressed and belongs to the electroneutral cation-chloride cotransporters, which are evolutionarily conserved from protists to humans, confirming their physiological significance . Dysfunction of SLC12A4 has been linked to various pathological conditions, including kidney disorders and hypertension, making it an important target for research in multiple fields .

What types of SLC12A4 antibodies are available for research applications?

Various types of SLC12A4 antibodies are available, each with distinct characteristics:

The choice depends on experimental needs, with polyclonal antibodies offering broader epitope recognition but potentially higher background, while monoclonal antibodies provide higher specificity for particular epitopes .

How should I validate the specificity of an SLC12A4 antibody before experimental use?

Proper validation of SLC12A4 antibodies is critical for experimental reliability. A comprehensive validation approach includes:

• Western blot analysis: Verify that the antibody detects a band at the expected molecular weight (approximately 121 kDa for SLC12A4) .

• Positive controls: Use cell lines known to express SLC12A4, such as HeLa cells, which have been confirmed to express detectable levels of the protein .

• Epitope mapping: Check the immunogen sequence information (often provided by manufacturers) to understand which region of SLC12A4 the antibody targets .

• Cross-reactivity testing: Examine reactivity across different species if performing comparative studies. Many SLC12A4 antibodies show reactivity with human, mouse, and rat samples .

• Knockout/knockdown validation: If possible, test the antibody in SLC12A4 knockout or knockdown systems to confirm specificity.

• Peptide competition assay: Use a blocking peptide containing the target epitope to demonstrate binding specificity.

A properly validated antibody should show consistent results across different experimental conditions and match expected expression patterns in tissues known to express SLC12A4 .

What are the optimal conditions for using SLC12A4 antibodies in Western blot applications?

For optimal Western blot results with SLC12A4 antibodies:

Sample preparation:

• Prepare whole cell lysates from appropriate cell types (HeLa cells are commonly used)

• Use complete lysis buffers containing protease inhibitors to prevent degradation

• Optimize protein loading (typically 20-50 μg per lane)

Electrophoresis conditions:

• Use lower percentage gels (6-8%) for better resolution of the 121 kDa SLC12A4 protein

• Include positive control lysates

Transfer and detection:

• Ensure complete transfer of high molecular weight proteins (longer transfer times may be necessary)

• Recommended dilution ranges: 1:500-1:1000 for most SLC12A4 antibodies

• Blocking: 5% non-fat milk or BSA in TBST (optimization may be required)

• Primary antibody incubation: Overnight at 4°C typically yields better results

Expected results:

• The observed molecular weight should be approximately 121 kDa

• Multiple bands may indicate isoforms, degradation products, or post-translational modifications

Follow manufacturer-specific protocols when available, as optimal conditions may vary between different antibody clones .

What are the critical considerations for successful immunohistochemistry with SLC12A4 antibodies?

Successful IHC with SLC12A4 antibodies requires attention to several critical factors:

Tissue processing and fixation:

• Paraffin embedding is commonly used for SLC12A4 detection

• Optimal fixative: 10% neutral buffered formalin (excessive fixation may mask epitopes)

Antigen retrieval:

• TE buffer pH 9.0 is suggested for many SLC12A4 antibodies

• Alternative: citrate buffer pH 6.0 (protocol optimization may be necessary)

• Heat-induced epitope retrieval (HIER) methods are typically effective

Antibody dilution and incubation:

• Recommended dilution range: 1:50-1:500 for IHC applications

• Incubation time: Typically overnight at 4°C or 1-2 hours at room temperature

Detection systems:

• DAB (3,3'-diaminobenzidine) is commonly used for colorimetric detection

• For fluorescence applications, select secondary antibodies with minimal background in the tissue of interest

Controls:

• Positive tissue controls: Human liver cancer tissue has shown positive staining

• Other tissues with validated expression: Human adrenal gland, placenta, thyroid, and colon tissues

Expected staining pattern:

• Cytoplasmic/membranous staining pattern in positive cells

• Expression patterns may vary across tissue types due to differential expression levels

Tissue-specific optimization of dilutions and incubation conditions is recommended for best results .

How can I troubleshoot weak or absent signal when using SLC12A4 antibodies?

When facing weak or absent signals with SLC12A4 antibodies, consider the following troubleshooting approaches:

For Western blot:

• Protein degradation: Ensure proper sample handling with complete protease inhibitors

• Insufficient protein: Increase total protein loading (30-50 μg may be necessary)

• Transfer issues: For the 121 kDa SLC12A4 protein, optimize transfer conditions (lower voltage for longer time)

• Antibody concentration: Try more concentrated antibody dilutions (e.g., 1:250 instead of 1:1000)

• Detection system: Switch to more sensitive detection methods (e.g., enhanced chemiluminescence)

• Exposure time: Increase exposure time during imaging

For IHC/ICC:

• Fixation issues: Over-fixation can mask epitopes; optimize fixation time

• Antigen retrieval: Compare different antigen retrieval methods (TE buffer pH 9.0 vs. citrate buffer pH 6.0)

• Antibody penetration: Ensure adequate permeabilization for intracellular epitopes

• Signal amplification: Consider using biotin-streptavidin or tyramine signal amplification systems

• Endogenous enzyme blocking: Ensure complete blocking of endogenous peroxidases or phosphatases

General considerations:

• Antibody storage: Improper storage can reduce activity; follow manufacturer recommendations for storage at -20°C

• Tissue-specific expression: Verify that SLC12A4 is expressed in your tissue/cell of interest

• Epitope accessibility: The targeted epitope may be masked by protein interactions or modifications

If problems persist, consider testing an alternative antibody that targets a different epitope of SLC12A4 .

What are the important controls to include when performing immunoprecipitation with SLC12A4 antibodies?

When performing immunoprecipitation (IP) with SLC12A4 antibodies, include these essential controls:

Input control:

• Reserve 5-10% of the pre-immunoprecipitation lysate to confirm target protein presence in starting material

Negative controls:

• Isotype control: Use matched isotype IgG (e.g., rabbit IgG for rabbit SLC12A4 antibodies) to assess non-specific binding

• Null cell line: Where available, use cells that don't express SLC12A4 or knockdown/knockout models

• No-antibody control: Process samples without primary antibody to detect non-specific binding to beads

Technical controls:

• Pre-clearing step: Pre-clear lysates with protein A/G beads to reduce non-specific binding

• Washing stringency gradient: Test different washing buffer stringencies to optimize signal-to-noise ratio

Confirmatory analysis:

• After IP, confirm SLC12A4 pulldown by Western blot using a different SLC12A4 antibody that recognizes a separate epitope

Recommended conditions:

• Antibody amount: 0.5-4.0 μg for 1.0-3.0 mg of total protein lysate

• Validated cell types: HeLa cells have shown successful IP with SLC12A4 antibodies

• Buffer composition: Use buffers containing protease inhibitors to prevent degradation

Proper optimization of antibody concentration and washing conditions is crucial for successful SLC12A4 immunoprecipitation .

How do different epitope targets affect SLC12A4 antibody performance?

The epitope target is a critical factor affecting SLC12A4 antibody performance across different applications:

N-terminal epitopes (AA 1-110):

• Often accessible in native protein conformations

• Useful for applications with intact proteins (IP, Flow cytometry)

• May be affected by N-terminal processing or modifications

• Examples include monoclonal antibodies targeting AA 1-110

Internal region epitopes:

• May be inaccessible in folded proteins but exposed in denatured conditions

• Often work well in Western blot applications

• May be less effective for IP of native proteins

• Several commercial antibodies target internal regions of SLC12A4

C-terminal epitopes (cytoplasmic domain):

• The C-terminal region (AA 891-1085) contains important regulatory domains

• ZooMAb rabbit recombinant antibodies target epitopes within 20 amino acids from the cytoplasmic domain

• Often effective for detecting regulatory modifications

• May be masked by protein interactions in some contexts

Functional domains:

• Antibodies targeting transport-specific domains may affect protein function

• Useful for functional blocking experiments

• Important to consider when studying transport activity

When selecting an SLC12A4 antibody, consider whether the epitope is accessible in your experimental conditions and whether it's in a region relevant to your research question .

What approaches can be used to study SLC12A4 subcellular localization in different cell types?

Multiple complementary approaches can be employed to study SLC12A4 subcellular localization:

Immunofluorescence microscopy:

• Fixed cells: Use paraformaldehyde fixation (typically 4%) followed by permeabilization

• Recommended dilution: 0.25-2 μg/mL for immunofluorescence applications

• Co-stain with organelle markers (e.g., plasma membrane, ER, Golgi markers)

• Use high-resolution confocal microscopy for detailed localization

Cell fractionation and Western blot:

• Separate cellular compartments (membrane, cytosol, nucleus)

• Probe fractions with SLC12A4 antibodies (1:500-1:1000 dilution)

• Include fraction-specific markers as controls (e.g., Na⁺/K⁺-ATPase for plasma membrane)

Immunoelectron microscopy:

• For ultrastructural localization at high resolution

• Special fixation and embedding protocols are required

• Use gold-conjugated secondary antibodies for visualization

Live-cell imaging:

• For dynamic localization studies, consider generating fluorescently tagged SLC12A4 constructs

• Validate that tagging doesn't affect localization by comparison with antibody staining

Tissue-specific considerations:

• Different cell types may show distinct localization patterns

• In polarized epithelial cells, SLC12A4 may show specific membrane domain localization

• Human cell lines with validated expression include HeLa and K562 cells

Combining multiple approaches provides the most comprehensive understanding of SLC12A4 subcellular distribution and trafficking .

How can I design experiments to study regulation of SLC12A4 expression and activity?

To study SLC12A4 regulation comprehensively, design experiments addressing multiple levels of control:

Transcriptional regulation:

• mRNA expression analysis:

  • qRT-PCR to quantify SLC12A4 transcripts under different conditions

  • RNA-seq for genome-wide expression profiling

  • Consider isoform-specific primers to distinguish transcript variants

• Promoter analysis:

  • Reporter assays with SLC12A4 promoter constructs

  • ChIP assays to identify transcription factor binding

  • CRISPR-based approaches to modify regulatory elements

Post-transcriptional regulation:

• Protein stability studies:

  • Cycloheximide chase experiments with Western blot detection (1:500-1:1000 antibody dilution)

  • Pulse-chase labeling

  • Proteasome/lysosome inhibitor treatments

• Translational control:

  • Polysome profiling

  • Translation inhibitor studies

Functional regulation:

• Transport activity assays:

  • 86Rb⁺ flux measurements for potassium transport

  • Fluorescent ion indicators

  • Electrophysiological recordings

• Cell swelling response:

  • Hypotonic challenge assays (SLC12A4 is activated by cell swelling)

  • Volume regulation measurements

  • Paired with antibody detection of SLC12A4 redistribution

Protein interactions:

• Co-immunoprecipitation:

  • Use 0.5-4.0 μg antibody per 1.0-3.0 mg protein lysate

  • Follow with mass spectrometry to identify interaction partners

  • Validate with reciprocal IP experiments

• Proximity labeling:

  • BioID or APEX2 fusions to identify proximal proteins

For all protein detection, Western blot verification with SLC12A4 antibodies remains a critical validation tool across experimental approaches .

What are key considerations when studying SLC12A4 in the context of human disease models?

When investigating SLC12A4 in human disease contexts, consider these critical factors:

Tissue-specific expression patterns:

• SLC12A4 expression varies across tissues; validate expression in your disease model

• IHC studies have confirmed expression in human liver cancer, thyroid cancer, colon cancer, adrenal gland, and placenta tissues

• Use appropriate dilutions (1:50-1:500 for IHC) for reliable detection

Disease relevance:

• SLC12A4 dysfunction has been implicated in:

  • Kidney disorders and hypertension

  • Cell volume regulation abnormalities

  • Ion transport defects in epithelial tissues

• Consider these known associations when designing disease-relevant experiments

Human sample considerations:

• For paraffin-embedded human tissues:

  • Recommended antigen retrieval: TE buffer pH 9.0 or citrate buffer pH 6.0

  • Account for variations in fixation protocols between clinical samples

  • Include appropriate tissue-matched controls

Model systems:

• Cell lines: HeLa cells have validated SLC12A4 expression

• Patient-derived samples: Primary cells or tissues may better represent disease states

• Genetic models: Consider CRISPR-Cas9 modification to create disease-relevant mutations

Comparative studies:

• Compare SLC12A4 expression/function between:

  • Normal vs. diseased tissue (e.g., cancer vs. adjacent normal tissue)

  • Treatment conditions (drug responses, environmental changes)

  • Different disease stages or severities

Functional correlation:

• Correlate SLC12A4 expression changes with functional outcomes (ion transport, cell volume regulation)

• Consider the involvement of related transporters from the SLC12 family for comprehensive analysis

Always validate antibody performance in each specific disease model or tissue type being studied .

How can post-translational modifications of SLC12A4 affect antibody recognition?

Post-translational modifications (PTMs) of SLC12A4 can significantly impact antibody recognition in various ways:

Phosphorylation effects:

• SLC12A4 contains numerous phosphorylation sites, particularly in regulatory domains

• Phosphorylation can alter epitope accessibility or recognition

• Phosphorylation-specific antibodies can be used to study regulatory events

• For total SLC12A4 detection, choose antibodies targeting regions less likely to be modified

Glycosylation considerations:

• SLC12A4 contains potential N-glycosylation sites in extracellular domains

• Glycosylation can mask epitopes or create steric hindrance

• May cause molecular weight shifts in Western blot (appearing larger than calculated 121 kDa)

• Treatment with glycosidases prior to analysis may improve detection in some cases

Strategies for comprehensive detection:

• Multi-epitope approach: Use antibodies targeting different regions of SLC12A4

• Modification-specific detection: Use phospho-specific antibodies when studying regulatory events

• Sample treatment: Consider phosphatase treatment to eliminate phosphorylation-dependent recognition issues

Experimental validation:

• When PTMs are suspected to affect antibody binding, validate with recombinant proteins containing or lacking specific modifications

• Compare different sample preparation methods (denaturing vs. native conditions)

• For definitive characterization, consider mass spectrometry analysis of purified SLC12A4

Understanding the specific epitope targeted by your antibody is crucial for interpreting results when studying modified forms of SLC12A4 .

What methodological approaches are recommended for quantifying SLC12A4 expression levels?

Accurate quantification of SLC12A4 expression requires careful methodological considerations:

Western blot quantification:

• Sample preparation standardization:

  • Equal protein loading (verify with total protein stains or housekeeping proteins)

  • Consistent lysis conditions to ensure complete protein extraction

  • Include calibration standards when possible

• Optimal antibody conditions:

  • Use validated dilutions (1:500-1:1000 for most SLC12A4 antibodies)

  • Ensure detection is in the linear range of the assay

• Analysis approach:

  • Normalize to appropriate loading controls

  • Use digital imaging with analysis software for densitometry

  • Report relative expression changes rather than absolute values unless calibration standards are used

Immunohistochemical quantification:

• Staining optimization:

  • Standardize all steps of the IHC protocol

  • Process all samples in parallel when possible

  • Use recommended dilutions (1:50-1:500)

• Scoring methods:

  • H-score (combines intensity and percentage of positive cells)

  • Digital image analysis for objective quantification

  • Blinded assessment by multiple observers

Flow cytometry quantification:

• For cell surface or intracellular SLC12A4 detection

• Include fluorescence minus one (FMO) and isotype controls

• Use median fluorescence intensity (MFI) for comparison between conditions

mRNA quantification:

• qRT-PCR with validated SLC12A4-specific primers

• Include multiple reference genes for normalization

• Consider absolute quantification with standard curves when comparing across different experiments

For all quantification methods, biological replicates and appropriate statistical analysis are essential for reliable results .

What are the functional implications of studying different SLC12A4 isoforms with antibodies?

SLC12A4 exists in multiple isoforms due to alternative splicing, with important functional implications for antibody-based studies:

Known isoform diversity:

• Multiple alternatively spliced transcript variants encoding distinct isoforms have been identified

• Isoform 4 specifically has been reported to lack transport activity

• Different isoforms may have distinct tissue distribution and functional roles

Antibody selection considerations:

• Epitope location: Determine whether your antibody targets regions common to all isoforms or isoform-specific sequences

• Expected banding patterns: Multiple bands in Western blot may represent different isoforms rather than non-specific binding

• Isoform-specific antibodies: Consider using antibodies that can distinguish between functionally distinct isoforms

Experimental design implications:

• Functional correlation: When studying transport function, consider which isoforms are being detected

• Tissue specificity: Different tissues may express distinct isoform profiles

• Disease relevance: Altered isoform expression ratios may occur in pathological conditions

Validation approaches:

• Recombinant isoform expression: Test antibody reactivity against individually expressed isoforms

• RNA analysis: Correlate protein detection with isoform-specific mRNA expression

• Mass spectrometry: For definitive isoform identification in complex samples

Understanding which SLC12A4 isoforms your antibody detects is crucial for correctly interpreting functional studies, particularly when transport activity is being assessed .

How can I integrate SLC12A4 antibody-based detection with functional transport studies?

Integrating SLC12A4 protein detection with functional transport analysis provides powerful insights into structure-function relationships:

Correlation of expression and function:

• Parallel analysis:

  • Measure SLC12A4 protein levels by Western blot (1:500-1:1000 dilution)

  • Simultaneously assess K⁺-Cl⁻ cotransport activity in the same samples

  • Plot correlation between expression and function across conditions

• Manipulation approaches:

  • Overexpress or knock down SLC12A4 and measure resulting changes in transport

  • Verify expression changes with antibody detection

  • Quantify dose-response relationships

Localization and function studies:

• Surface expression:

  • Use cell surface biotinylation followed by SLC12A4 immunoprecipitation (0.5-4.0 μg antibody)

  • Correlate surface expression with transport capacity

  • Examine trafficking in response to stimuli

• Subcellular distribution:

  • Immunofluorescence microscopy (0.25-2 μg/mL antibody)

  • Relate redistribution to functional changes

  • Co-localize with regulatory partners

Functional modification analysis:

• Phosphorylation state:

  • Use phospho-specific antibodies if available

  • Correlate phosphorylation with transport activation/inhibition

  • Apply phosphorylation site mutants for validation

• Protein-protein interactions:

  • Immunoprecipitate SLC12A4 complexes and identify interaction partners

  • Disrupt specific interactions and measure transport consequences

  • Use proximity ligation assays to visualize interactions in situ

Experimental conditions affecting transport:

• Cell swelling activates SLC12A4-mediated transport

• Design experiments to test expression-function relationships under physiological activation conditions

This integrated approach provides mechanistic insights beyond what either protein detection or functional studies alone can offer .